Aurora Investment Counsel’s BioLineRX BLRX Stock Holding History

Aurora Investment Counsel’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-24	Closed	-$16K	–	109
2017 Q4	$16K	Buy	+24	New	+$15.8K	0.01%	107

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Aurora Investment Counsel's BLRX Position: Q1 2018 in Review

Aurora Investment Counsel sold out of BioLineRX (BLRX) in Q1 2018, closing a stake of 24 shares — an estimated $16K sold.

Aurora Investment Counsel first reported a position in BLRX in Q4 2017 and held it in 1 quarter. The position peaked at $16K in Q4 2017. 28 funds tracked by Wall St. Rank hold BLRX as of Q1 2018.

Aurora Investment Counsel reported no remaining BioLineRX position as of Q1 2018 after selling out during the quarter.
Aurora Investment Counsel sold 24 BioLineRX shares in Q1 2018, an estimated $16K.
Aurora Investment Counsel first reported a position in BioLineRX in Q4 2017 and held it in 1 quarter.
Aurora Investment Counsel's BioLineRX position peaked at $16K in Q4 2017.
28 funds tracked by Wall St. Rank held BioLineRX as of Q1 2018.

Based on Aurora Investment Counsel's 13F filing for Q1 2018, filed 9 Apr 2018.